Lebrikizumab in asthma: an anti-IL-13 effect that would not replicate

What was tried

Roche ran a Phase 3 trial in adolescents (NCT01875003) of lebrikizumab, an anti-interleukin-13 monoclonal antibody, in uncontrolled asthma on inhaled corticosteroids plus a second controller. The study randomized 346 patients 1:1:1 to lebrikizumab 37.5 mg, 125 mg, or placebo every four weeks, with the rate of asthma exacerbations over 52 weeks as the primary endpoint. It was terminated, and the registry reason reads "Sponsor decision to discontinue lebrikizumab development for the treatment of asthma." That decision was made upstream, in the two adult pivotal trials, LAVOLTA I and LAVOLTA II, which together enrolled 2148 patients and reported first (Hanania et al, 2016).

The biological hypothesis

Interleukin-13 is a type 2 cytokine that drives airway eosinophilia, IgE class switching, goblet cell mucus, and periostin release. Lebrikizumab binds IL-13 and blocks it (ChEMBL CHEMBL1743035). The target is well anchored to the disease: Open Targets scores the IL13 to asthma association at 0.70, with a genetic association component of 0.95. The Phase 2 program concentrated benefit in patients with high type 2 biomarkers, so the pivotal design enriched for them, defining biomarker-high as serum periostin at or above 50 ng/mL or blood eosinophils at or above 300 cells per microliter. The bet was simple. Block IL-13 in the patients whose biology is IL-13 driven, and exacerbations fall.

What actually happened

The two pivotal trials disagreed with each other. In LAVOLTA I, biomarker-high patients on the 37.5 mg dose had an exacerbation rate ratio of 0.49 versus placebo (95% CI 0.34 to 0.69, p<0.0001), and the 125 mg dose gave 0.70 (0.51 to 0.95, p=0.0232). In LAVOLTA II, the same doses gave 0.74 (0.54 to 1.01, p=0.0609) and 0.74 (0.54 to 1.02, p=0.0626) (Hanania et al, 2016). The replicate trial missed. The authors concluded that lebrikizumab "did not consistently show significant reduction in asthma exacerbations." The adolescent trial that followed was small and split the same way: exacerbation rates of 0.43 events per patient-year on placebo against 0.26 and 0.21 on the two doses, with rate ratios of 0.60 (0.35 to 1.03) and 0.49 (0.28 to 0.83), and a high-dose FEV1 gain of 198 mL (53 to 342) (NCT01875003 results). Roche stopped the indication.

Failure mechanism, best guess

This was not target failure. Pharmacodynamic biomarkers confirmed IL-13 was engaged. The failure was effect size colliding with a biomarker that could not select the responders. IL-13 and IL-4 both signal through the IL-4 receptor alpha and STAT6, so neutralizing IL-13 alone leaves a parallel IL-4 arm intact. Periostin, the enrichment marker, behaved as a marker of type 2 inflammation in general rather than a predictor of who benefits from IL-13 blockade specifically. The honest read of LAVOLTA is that the true exacerbation effect sits near a rate ratio of 0.7, real but modest, while the program was sized and sold on the rosier Phase 2 estimate near 0.5. Two contrasts make the point. Dupilumab, which blocks the shared IL-4 receptor alpha and therefore both IL-4 and IL-13, succeeded in asthma. Lebrikizumab itself went on to reach approval in atopic dermatitis (ChEMBL max phase 4), a skin disease where IL-13 is more dominant. The molecule worked. The asthma indication and the periostin biomarker did not.

How to prevent this next time

Two quantitative tools would have changed the decision to run two identical pivotals.

First, a Bayesian predictive probability gate. Given the Phase 2 posterior, the probability that a confirmatory trial reaches significance is

PP(success)=∫θ​P(final success∣θ,interim data)⋅π(θ∣interim data)dθ

A single Phase 2 read with a point estimate near 0.5 but a wide interval feeds a posterior that places real mass on rate ratios of 0.7 and above, where a standard Poisson exacerbation trial is underpowered. That predictive probability, computed honestly, would have been well short of the comfort the team assumed.

Second, effect-size and base-rate discipline. Powering for a rate ratio of 0.5 when 0.7 is equally consistent with the data is the classic overstatement. A Poisson exacerbation endpoint needs far more accrued events to detect 0.7 than 0.5 at the same power, so the trials were structurally fragile. Set against an industry Phase 3 success rate near 58 percent (BIO, Informa, QLS, 2021), a fragile design in a crowded type 2 field warranted a validated predictive biomarker before commitment, not a prognostic one repurposed as predictive.

The single highest leverage change would have been to power LAVOLTA for a rate ratio near 0.7 with a prespecified Bayesian predictive-probability gate, and to validate periostin as a predictive biomarker in an independent cohort before locking two pivotal trials to it.

What this means for similar programs

IL-13 monotherapy for exacerbation reduction in asthma is now a documented dead end, while the same molecular class delivers at the IL-4 receptor alpha (dupilumab) or in atopic dermatitis (lebrikizumab, tralokinumab). The lesson generalizes to any type 2 cytokine target: separate the single node from the pathway it shares, and never let a prognostic biomarker stand in for a predictive one. The Claidex Mechanism Risk Score for IL13 is 37 (yellow), driven by a Phase 3 efficacy failure against an otherwise strong genetic anchor (Open Targets 0.70). A new IL-13 asthma program would need to resolve the receptor-sharing problem and bring a validated responder marker before it earns a pivotal.

Open questions

• Would an IL-13 plus IL-4 dual strategy outperform single-node blockade in periostin-high asthma, or is the IL-4 receptor alpha the only node that matters.
• Was periostin ever predictive of IL-13-specific benefit, or only a correlate of type 2 burden.
• Does adolescent airway biology differ enough from adult disease to justify a dedicated trial, or was the adolescent study underpowered by design.

Sources

1. Hanania NA, Korenblat P, Chapman KR, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II). Lancet Respiratory Medicine, 2016.

2. A Study of Lebrikizumab in Adolescent Participants With Uncontrolled Asthma. ClinicalTrials.gov NCT01875003, posted results, 2016 to 2026. https://clinicaltrials.gov/study/NCT01875003.

3. Bauer RN, Yang X, Staton TL, et al. Seasonal variability of lung function and Asthma Quality of Life in uncontrolled asthma (LAVOLTA analysis). BMJ Open Respiratory Research, 2019.

4. Open Targets Platform. IL13 to asthma association evidence. https://platform.opentargets.org/evidence/ENSG00000169194/MONDO_0004979.

5. ChEMBL. Lebrikizumab compound record (CHEMBL1743035), interleukin-13 inhibitor, max phase 4. https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1743035/.

6. Clinical Development Success Rates 2011 to 2020. BIO, Informa Pharma Intelligence, QLS Advisors, 2021. https://www.bio.org/clinical-development-success-rates-2011-2020.